Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Wallner, Paul E.
and
Konski, Andre
2008.
A Changing Paradigm in the Study and Adoption of Emerging Health Care Technologies: Coverage With Evidence Development.
Journal of the American College of Radiology,
Vol. 5,
Issue. 11,
p.
1125.
Retèl, Valesca P.
Bueno-de-Mesquita, Jolien M.
Hummel, Marjan J. M.
van de Vijver, Marc J.
Douma, Kirsten F. L.
Karsenberg, Kim
van Dam, Frits S. A. M.
van Krimpen, Cees
Bellot, Frank E.
Roumen, Rudi M. H.
Linn, Sabine C.
and
van Harten, Wim H.
2009.
Constructive Technology Assessment (CTA) as a tool in Coverage with Evidence Development: The case of the 70-gene prognosis signature for breast cancer diagnostics.
International Journal of Technology Assessment in Health Care,
Vol. 25,
Issue. 01,
p.
73.
CHALKIDOU, KALIPSO
TUNIS, SEAN
LOPERT, RUTH
ROCHAIX, LISE
SAWICKI, PETER T.
NASSER, MONA
and
XERRI, BERTRAND
2009.
Comparative Effectiveness Research and Evidence‐Based Health Policy: Experience from Four Countries.
The Milbank Quarterly,
Vol. 87,
Issue. 2,
p.
339.
Carbonneil, Cédric
Quentin, Fabienne
and
Lee-Robin, Sun Hae
2009.
A common policy framework for evidence generation on promising health technologies.
International Journal of Technology Assessment in Health Care,
Vol. 25,
Issue. S2,
p.
56.
O'Malley, Sue P.
Selby, Warwick S.
and
Jordan, Ernest
2009.
A successful practical application of Coverage with Evidence Development in Australia: Medical Services Advisory Committee interim funding and the PillCam® Capsule Endoscopy Register.
International Journal of Technology Assessment in Health Care,
Vol. 25,
Issue. 03,
p.
290.
Ballini, Luciana
Minozzi, Silvia
Negro, Antonella
Pirini, Giampiero
and
Grilli, Roberto
2010.
A method for addressing research gaps in HTA, developed whilst evaluating robotic-assisted surgery: a proposal.
Health Research Policy and Systems,
Vol. 8,
Issue. 1,
Patrick, Hannah
Gallaugher, Sally
Czoski-Murray, Carolyn
Wheeler, Robert
Chattle, Marc
Marlow, Mirella
Lyratzopoulos, Georgios
and
Campbell, Bruce
2010.
Usefulness of a short-term register for health technology assessment where the evidence base is poor.
International Journal of Technology Assessment in Health Care,
Vol. 26,
Issue. 1,
p.
95.
Carlson, Josh J.
Sullivan, Sean D.
Garrison, Louis P.
Neumann, Peter J.
and
Veenstra, David L.
2010.
Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.
Health Policy,
Vol. 96,
Issue. 3,
p.
179.
Lexchin, Joel
2011.
Coverage with Evidence Development for Pharmaceuticals: A Policy in Evolution?.
International Journal of Health Services,
Vol. 41,
Issue. 2,
p.
337.
Mortimer, Duncan
Li, Jing Jing
Watts, Jennifer
and
Harris, Anthony
2011.
Breaking up is hard to do: the economic impact of provisional funding contingent upon evidence development.
Health Economics, Policy and Law,
Vol. 6,
Issue. 4,
p.
509.
Chalkidou, Kalipso
Tunis, Sean
Whicher, Danielle
Fowler, Robert
and
Zwarenstein, Merrick
2012.
The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research.
Clinical Trials,
Vol. 9,
Issue. 4,
p.
436.
Ladabaum, Uri
Brill, Joel V.
Sonnenberg, Amnon
Shaheen, Nicholas J.
Inadomi, John
Wilcox, C. Mel
Park, Walter G.
Hur, Chin
and
Pasricha, Pankaj J.
2013.
How to Value Technological Innovation: A Proposal for Determining Relative Clinical Value.
Gastroenterology,
Vol. 144,
Issue. 1,
p.
5.
Longworth, Louise
Youn, JiHee
Bojke, Laura
Palmer, Stephen
Griffin, Susan
Spackman, Eldon
and
Claxton, Karl
2013.
When Does NICE Recommend the Use of Health Technologies Within a Programme of Evidence Development?.
PharmacoEconomics,
Vol. 31,
Issue. 2,
p.
137.
Franken, Margreet G.
van Gils, Chantal W.M.
Gaultney, Jennifer G.
Delwel, Gepke O.
Goettsch, Wim
Huijgens, Peter C.
Steenhoek, Adri
Punt, Cornelis J.A.
Koopman, Miriam
Redekop, William K.
and
Uyl-de Groot, Carin A.
2013.
Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands.
European Journal of Cancer,
Vol. 49,
Issue. 1,
p.
8.